Raptor Pharmaceuticals Provides Update of Produc...(BBB and to investigate the potential for...),Health

Preclinical Testing Completed for WntTide(TM) in Osteoporosis

Raptor has completed preclinical testing of WntTide, for its osteoporosis program, utilizing Mesd and engineered Mesd-based peptides, and is awaiting the final report of WntTide in a well-accepted preclinical model widely used to test reduction in bone loss. WntTide may aid in increasing bone density in the treatment of osteoporosis and rheumatoid arthritis. The Company has run selected preclinical studies to move this program to a point where its utility can be realistically assessed for further investment. If results are positive, the Company plans to seek a collaborative arrangement with a partner for further development of the peptide in this very widespread and expensive disease. The Company licensed Mesd from Washington University, St. Louis, for the treatment of osteoporosis and cancer in November 2006.

Scientific Publication Update

Raptor researchers published a paper entitled "Minimization of the third domain of the LDL receptor-associated protein (RAP)," which describes their efforts to develop a readily-manufactured RAP-based peptide to act as a delivery vehicle to the liver. Raptor authors include Sara Isbell, Simone Haslam and Dr. Todd Zankel. The Internet link to the paper, published by Biochemical and Biophysical Research Communications dated September 28, 2007 in volume 361, issue 3, pages 758 to 762, will be posted in the Product Programs, RAP section of our website http://www.raptorpharma.com.

About Raptor

Raptor Pharmaceuticals Corp.'s sole business is its 100% ownership of Raptor Pharmaceutical Inc., a development stage biotechnology company which bioengineers novel drugs and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related prot
'/>"/>